Good
Partially Aligned
Patient Risk:
Moderate
Summary
Most claims match the provided COSENTYX label excerpts (indications, IL-17A mechanism, and infection risk/opportunistic infections). However, several infection details are not supported verbatim by the provided label text (localized infection risk; respiratory/skin/GI sequencing; specific vaccination suggestions for flu/pneumonia while on treatment).
Category Scores
Accurate Statements
Cosentyx is approved for the treatment of psoriatic arthritis.
Section 1.2 Psoriatic Arthritis
Cosentyx is approved for the treatment of axial spondyloarthritis.
Sections 1.3 (Ankylosing Spondylitis) and 1.4 (Non-Radiographic Axial Spondyloarthritis)
Cosentyx works by blocking the activity of interleukin-17A (IL-17A).
Section 12.1 Mechanism of Action (selectively binds IL-17A and inhibits its interaction with IL-17 receptor)
Cosentyx use carries a risk of infections.
Section 5.1 Infections (COSENTYX may increase the risk of infections)
More serious infections, including opportunistic infections, have been reported with Cosentyx use.
Section 5.1 Infections (Serious bacterial, viral, and fungal opportunistic infections, and some fatal infections have been reported)
Unsupported Statements
Cosentyx is approved for the treatment of moderate to severe rheumatoid arthritis.
The provided label excerpts do not include a rheumatoid arthritis indication (Sections 1.1–1.6 cover plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis, enthesitis-related arthritis, and hidradenitis suppurativa).
The most common infections associated with Cosentyx use are upper respiratory tract infections.
The provided excerpts state higher rates of common infections but do not specify 'upper respiratory tract infections' as the most common.
Upper respiratory tract infections associated with Cosentyx use include the common cold.
The provided excerpts do not list the common cold.
Upper respiratory tract infections associated with Cosentyx use include sinusitis.
The provided excerpts do not list sinusitis.
The risk of infections with Cosentyx use may be localized to specific regions of the body.
The provided excerpts do not state that infection risk may be localized to specific body regions.
In patients with rheumatoid arthritis treated with Cosentyx, the risk of infections was highest in the respiratory tract.
No rheumatoid arthritis indication/population is provided in the excerpted labeling, and the provided excerpts do not include respiratory-vs-skin-vs-GI infection ranking.
In patients with rheumatoid arthritis treated with Cosentyx, the risk of infections was followed by the skin.
The provided excerpts do not include this skin-followed ranking, and they do not provide the rheumatoid arthritis infection distribution.
In patients with rheumatoid arthritis treated with Cosentyx, the risk of infections was followed by the gastrointestinal tract.
The provided excerpts do not include this gastrointestinal-followed ranking, and they do not provide the rheumatoid arthritis infection distribution.
Patients with rheumatoid arthritis who experience respiratory tract infections may be at higher risk of developing more serious infections such as pneumonia.
The provided excerpts do not include pneumonia or escalation-risk phrasing tied to rheumatoid arthritis/respiratory tract infections.
Patients should get vaccinated against infections such as the flu while taking Cosentyx.
The provided excerpt (Section 5.7) states to avoid live vaccines; it does not support a directive to receive 'flu' vaccination while taking Cosentyx.
Patients should get vaccinated against infections such as pneumonia while taking Cosentyx.
The provided excerpts do not mention pneumonia vaccination, and Section 5.7 only states to avoid live vaccines.
Contradictions
Important Omissions
If giving vaccination-related guidance, Section 2.1 and Section 5.7 support pre-treatment vaccination completion per immunization guidelines and avoidance of live vaccines; the AI response instead provides specific 'flu'/'pneumonia' vaccination directives without reflecting the 'avoid live vaccines' constraint.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Most safety statements about infections and opportunistic infections align with the label excerpts. However, several infection-specific details and the vaccination directives are not supported by the provided label text, potentially leading to inaccurate counseling (notably live-vaccine avoidance is not addressed).
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Partially Aligned
Primary Issue
Several safety/vaccination and infection-detail claims are not supported by the provided prescribing information excerpts, and rheumatoid arthritis indication is not present in the excerpted label sections.
Suggested Improvement
Restrict claims to the provided label-supported indications (remove rheumatoid arthritis unless full label supports it), and for vaccines align wording to the label: complete age-appropriate vaccinations prior to initiation per immunization guidelines and avoid live vaccines during treatment.